Gland Pharma Limited
GLAND
Rank in Stocks
#3298
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Share Price
$32.32
Market Cap
$5.33B
Change (1 day)
-3.01%
Change (1 year)
47.99%
Country
IN
Trade Gland Pharma Limited (GLAND)
Category
Healthcare
P/E ratio for Gland Pharma Limited (GLAND)
P/E ratio as of October 2026 TTM: 44.41
According to Gland Pharma Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 44.41. At the end of 2024 the company had a P/E ratio of 38.68.
P/E ratio history for Gland Pharma Limited from 2017 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 44.41 | 21.21% |
| 2025 | 36.64 | -5.28% |
| 2024 | 38.68 | 44.69% |
| 2023 | 26.73 | -39.70% |
| 2022 | 44.34 | 12.83% |
| 2021 | 39.30 | 7.72% |
| 2020 | 36.48 | -44.52% |
| 2019 | 65.75 | -28.95% |
| 2018 | 92.54 | 35.80% |
| 2017 | 68.15 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -21.28% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.